Question 1

What is Spero Therapeutics?

Accepted Answer

Spero Therapeutics is a Company.

Question 2

How often does Spero Therapeutics appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 21 articles.

Question 3

When was Spero Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jul 08, 2026.

Question 4

When was Spero Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 27, 2026.

Question 5

What is Spero Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 23 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Spero Therapeutics in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Spero Therapeutics?

Accepted Answer

Spero $105M royalty financing (Jul 14, 2026, 9 articles).

Question 8

How did the "Spero $105M royalty financing" event impact Spero Therapeutics?

Accepted Answer

Spero secured $105M non-dilutive financing, extending cash runway into H2 2029 and funding SP001 development.

Question 9

How did the "Spero Therapeutics appoints new CMO" event impact Spero Therapeutics?

Accepted Answer

Spero Therapeutics appointed a new CMO to lead clinical development of its lead asset SP001, signaling progress in its pipeline.

Question 10

How did the "Avacta appoints Patrick Vink Deputy Chairman" event impact Spero Therapeutics?

Accepted Answer

Patrick Vink serves on the board of Spero Therapeutics.

Question 11

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.